Can targeted therapy be Successful without metronomic scheduling?

Current Topics in Medicinal Chemistry

Volumn 12, Issue 15, 2012, Pages 1639-1642

  André, Nicolas ^a,b,c   Pasquier, Eddy ^c,d   Kamen, Barton ^c,e  

^a TIMONE HOSPITAL   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c Metronomics Global Health Initiative   (France)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

Cancer; Chemotherapy; Metronomic; MTD; Targeted therapy

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BEVACIZUMAB; CELECOXIB; CYCLOPHOSPHAMIDE; DASATINIB; ERLOTINIB; GEFITINIB; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METFORMIN; METHOTREXATE; NILOTINIB; PENTOSTATIN; PROPANOL; SUNITINIB; TEMOZOLOMIDE; TRASTUZUMAB; VINBLASTINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMORADIOTHERAPY; CHRONIC MYELOID LEUKEMIA; CYTOTOXICITY; DIABETES MELLITUS; DOSAGE SCHEDULE COMPARISON; DRUG ACTIVITY; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG POTENCY; DRUG TARGETING; GENETIC HETEROGENEITY; HUMAN; HYPERTENSION; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; METRONOMIC CHEMOTHERAPY; MOLECULARLY TARGETED THERAPY; PAIN; SENSITIVITY AND SPECIFICITY; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING;

ADMINISTRATION, METRONOMIC; ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; TREATMENT OUTCOME;

EID: 84867610876     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612803531432     Document Type: Article

References (38)

1. Adams, G.P.; Weiner, L.M. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 2005, 23(9), 1147-5.
2. Gschwind, A.; Fischer, O.M.; Ullrich, A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat. Rev. Cancer, 2004, 4(5), 361-370.
3. Slamon, D.J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram, M.; Baselga, J.; Norton, L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med., 2001, 344(11), 783-792.
4. Ranpura, V.; Hapani, S.; Wu, S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA. 2011; 305(5), 487-494.
5. O'Brien, S.; Abboud, C.N.; Akhtari, M.; Altman, J.; Berman, E.; Deangelo, D.J.; Devine, S.; Fathi, A.T.; Gotlib, J.; Jagasia, M.; Moore, J.O.; Pinilla-Ibarz, J.; Radich, J.P.; Reddy, V.V.; Shah, N.P.; Shami, P.J.; Smith, B.D.; Snyder, D.S.; Wetzler, M.; Yunus, F. Chronic myelogenous leukemia. J. Natl. Compr. Canc. Netw., 2012, 10(1), 64-110.
6. Paez, J.G.; Jänne, P.A.; Lee, J.C.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F.J.; Lindeman, N.; Boggon, T.J.; Naoki, K.; Sasaki, H.; Fujii, Y.; Eck, M.J.; Sellers, W.R.; Johnson, B.E.; Meyerson, M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004, 304(5676), 1497-500.
7. Dancey J. mTOR signaling and drug development in cancer. Nat. Rev. Clin. Oncol., 2010, 7(4), 209-219.
8. Torino, F.; Corsello, S.M.; Longo, R.; Barnabei, A.; Gasparini, G. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat. Rev. Clin. Oncol., 2009, 6(4), 219-228.
9. Rees, M.L.; Khakoo, A.Y. Molecular mechanisms of hypertension and heart failure due to antiangiogenic cancer therapies. Heart Fail Clin., 2011, 7(3), 299-311.
10. Kelly, R.J.; Billemont, B.; Rixe, O. Renal toxicity of targeted therapies. Target Oncol. 2009, 4(2), 121-33.
11. Shi, H.; Zhang, C.J.; Chen, G.Y.; Yao, S.Q. Cell-based proteome profiling of potential dasatinib targets by use of affinity-based probes. J. Am. Chem. Soc., 2012, 134(6), 3001-14.
12. http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted.
13. Fojo, T. Commentary: Novel therapies for cancer: why dirty might be better. Oncologist. 2008, 13(3), 277-283.
14. Schroeder, A.; Heller, D.A.; Winslow, M.M.; Dahlman, J.E.; Pratt, G.W.; Langer, R.; Jacks, T. Anderson, D.G. Treating metastatic cancer with nanotechnology. Nat. Rev. Cancer. 2011,12(1), 39-50.
15. Jain, R.K.; Stylianopoulos, T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol., 2010,7(11), 653-664.
16. Weisberg, E.; Manley, P.W.; Breitenstein, W.; Brüggen, J.; Cowan-Jacob, S.W.; Ray, A.; Huntly, B.; Fabbro, D.; Fendrich, G.; Hall-Meyers, E.; Kung, A.L.; Mestan, J.; Daley, G.Q.; Callahan, L.; Catley, L.; Cavazza, C.; Azam, M.; Neuberg, D.; Wright, R.D.; Gilliland, D.G.; Griffin, J.D. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005, 7(2), 129-141.
17. Saglio, G.; Kim, D.W.; Issaragrisil, S.; le Coutre, P.; Etienne, G.; Lobo, C.; Pasquini, R.; Clark, R.E.; Hochhaus, A.; Hughes, T.P.; Gallagher, N.; Hoenekopp, A.; Dong, M.; Haque, A.; Larson, R.A.; Kantarjian, H.M. ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N. Engl. J. Med., 2010, 17, 362(24), 2251-2259.
18. Roth, B. Design of dihydrofolate reductase inhibitors from X-ray crystal structures. Fed. Proc., 1986, 45(12), 2765-2772.
19. Kati, W.M.; Acheson, S.A.; Wolfenden, R. A transition state in pieces: major contributions of entropic effects to ligand binding by adenosine deaminase. Biochemistry. 1992, 31(32), 7356-7366.
20. Litzow, M.R. Imatinib resistance: obstacles and opportunities. Arch Pathol. Lab. Med. 2006, 130(5), 669-679.
21. Kerbel, R.S., Kamen, B.A. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer, 2004, 4(6), 423-436.
22. Pasquier, E.; Kavallaris, M.; André, N. Metronomic chemotherapy: new rationale for new directions. Nat. Rev. Clin. Oncol. 2010, 7(8), 455-465.
23. Klement, G.L.; Kamen, B.A.; Nontoxic, fiscally responsible, future of oncology: could it be beginning in the Third World? J. Pediatr. Hematol. Oncol., 2011, 33(1), 1-3.
24. Skipper, H.E.; Schabel, F.M.; Jr, Mellett, L.B.; Montgomery, J.A.; Wilkoff, L.J.; Lloyd, H.H.; Brockman, R.W. Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother. Rep., 1970, 54(6), 431-450.
25. Weitman, S.D.; Glatstein, E. Kamen, B.A. Back to the basics: the importance of concentration x time in oncology. J. Clin. Oncol., 1993, 11(5), 820-821.
26. Kamen, B.A.; Rubin, E.; Aisner, J.; Glatstein, E. High-time chemotherapy or high time for low dose. J. Clin. Oncol., 2000, 18(16), 2935-2937.
27. Miller, K.D.; Sweeney, C.J.; Sledge G.W. Redefining the target: chemotherapeutics as antiangiogenics. J. Clin. Oncol., 2001 15, 19(4), 1195-1206.
28. André, N., Pasquier, E. For cancer, seek and destroy or live and let live? Nature. 2009,460(7253), 324.
29. Banissi, C.; Ghiringhelli, F.; Chen, L.; Carpentier, A.F. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol. Immunother., 2009, 58(10), 1627-1634.
30. Ghiringhelli, F.; Larmonier, N.; Schmitt, E.; Parcellier, A.; Cathelin, D., Garrido, C.; Chauffert, B.; Solary, E.; Bonnotte, B.; Martin, F. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamidewhich allows immunotherapy of established tumors to be curative. Eur. J. Immunol., 2004,34(2), 336-344.
31. Tanaka, H.; Matsushima, H.; Nishibu, A.; Clausen, B.E.; Takashima, A. Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducingdendritic cell maturation. Cancer Res., 2009, 69(17), 6987-6994.
32. Jones, M.K.; Wang, H.; Peskar, B.M.; Levin, E.; Itani, R.M.; Sarfeh, I.J.; Tarnawski, A.S. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat. Med., 1999 5(12), 1418-1423.
33. Pasquier, E.; Ciccolini, J.; Carre, M.; Giacometti, S.; Fanciullino, R., Pouchy, C.; Montero, M.P.; Serdjebi, C.; Kavallaris, M.; André, N. Propranolol potentiates the anti-angiogenic effects and antitumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget., 2011, 2(10), 797-809.
34. Guppy, A.; Jamal-Hanjani, M.; Pickering, L. Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer. Future Oncol., 2011, 7(6), 727-736.
35. Khan, Z.; Khan, N.; Tiwari, R.P.; Sah, N.K.; Prasad, G.B.; Bisen, P.S. Biology of Cox-2: an application in cancer therapeutics. Curr. Drug Targets. 2011, 12(7), 1082-1093.
36. Penel, N.; Duhamel, A.; Adenis, A.; Devos, P.; Isambert, N.; Clisant, S.; Bonneterre, J. Predictors for establishing recommended phase 2 doses: analysis of 320dose-seeking oncology phase 1 trials. Invest New Drugs. 2012, 30(2), 653-661.
37. Burgess, D.S. Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance. Chest. 1999, 115(3 Suppl),19S-23S.
38. DeRyke, C.A.; Lee, S.Y.; Kuti, J.L.; Nicolau, D.P. Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistance. Drugs. 2006, 66(1), 1-14.